



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA-2013-M-1321, FDA-2013-M-1322, FDA-2013-M-1323, FDA-2013-M-1362, FDA-2013-M-1363, FDA-2013-M-1364, FDA-2013-M-1365, FDA-2013-M-1488, and FDA-2013-M-1605]

Medical Devices; Availability of Safety and Effectiveness Summaries for Premarket Approval Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is publishing a list of premarket approval applications (PMAs) that have been approved. This list is intended to inform the public of the availability of safety and effectiveness summaries of approved PMAs through the Internet and the Agency's Division of Dockets Management.

ADDRESSES: Submit written requests for copies of summaries of safety and effectiveness data to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Please cite the appropriate docket number as listed in table 1 when submitting a written request. See the SUPPLEMENTARY INFORMATION section for electronic access to the summaries of safety and effectiveness.

FOR FURTHER INFORMATION CONTACT: Nicole Wolanski, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, rm. 1650, Silver Spring, MD 20993-0002, 301-796-6570.

SUPPLEMENTARY INFORMATION:

I. Background

In accordance with sections 515(d)(4) and (e)(2) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 360e(d)(4) and (e)(2)), notification of an order approving, denying, or withdrawing approval of a PMA will continue to include a notice of opportunity to request review of the order under section 515(g) of the FD&C Act. The 30-day period for requesting reconsideration of an FDA action under § 10.33(b) (21 CFR 10.33(b)) for notices announcing approval of a PMA begins on the day the notice is placed on the Internet. Section 10.33(b) provides that FDA may, for good cause, extend this 30-day period. Reconsideration of a denial or withdrawal of approval of a PMA may be sought only by the applicant; in these cases, the 30-day period will begin when the applicant is notified by FDA in writing of its decision.

The regulations provide that FDA publish a quarterly list of available safety and effectiveness summaries of PMA approvals and denials that were announced during that quarter. The following is a list of approved PMAs for which summaries of safety and effectiveness were placed on the Internet from October 1, 2013, through December 31, 2013. There were no denial actions during this period. The list provides the manufacturer's name, the product's generic name or the trade name, and the approval date.

Table 1.--List of Safety and Effectiveness Summaries for Approved PMAs Made Available From October 1, 2013, Through December 31, 2013

PMA No., Docket No.	Applicant	Trade Name	Approval Date
P040043/S051, FDA-2013-M-1323	W.L. Gore & Associates, Inc.	GORE® TAG® Thoracic Endoprosthesis	September 10, 2013
P970053/S011, FDA-2013-M-1362	Nidek Co., Ltd.	Nidek EC-5000 Excimer Laser System	September 30, 2013
P020050/S012, FDA-2013-M-1321	Alcon Research, Ltd.	ALLEGRETTO WAVE® Eye-Q Excimer Laser System	October 2, 2013

H120005, FDA-2013-M-1322	Kaneka Pharma America LLC	Kaneka Liposorber® LA-15 System	October 10, 2013
P130005, FDA-2013-M-1363	Cardiovascular Systems, Inc.	Diamondback 360® Coronary Orbital Arthroctomy System	October 21, 2013
P110033, FDA-2013-M-1364	Allergan	JUVÉDERM® VOLUMA™ XC	October 22, 2013
P100009, FDA-2013-M-1365	Abbott Vascular	MitraClip Clip Delivery System (MitraClip CDS)	October 24, 2013
P100026, FDA-2013-M-1488	NeuroPace, Inc.	RNS® System	November 14, 2013
P130006, FDA-2013-M-1605	W.L. Gore & Associates, Inc.	GORE® VIABAHN® Endoprosthesis & GORE® VIABAHB® Endoprosthesis with Heparin BioActive Surface	December 5, 2013

II. Electronic Access

Persons with access to the Internet may obtain the documents at

<http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/PMAApprovals/default.htm>.

Dated: March 7, 2014.

Leslie Kux,

Assistant Commissioner for Policy.